Northwest Biotherapeutics Secures New Loan Agreement
Ticker: NWBO · Form: 8-K · Filed: 2024-12-26T00:00:00.000Z
Sentiment: neutral
Topics: debt-financing, material-agreement
TL;DR
NWBO just took out a new loan, adding to their debt obligations.
AI Summary
On December 19, 2024, Northwest Biotherapeutics, Inc. entered into a material definitive agreement, specifically a loan agreement. This agreement creates a direct financial obligation for the registrant, indicating new debt financing for the company.
Why It Matters
This filing indicates Northwest Biotherapeutics has secured new debt financing, which could impact its financial flexibility and operational capacity.
Risk Assessment
Risk Level: medium — Entering into new debt agreements can increase financial risk, especially for companies in the development stage.
Key Players & Entities
- Northwest Biotherapeutics, Inc. (company) — Registrant
- December 19, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 0-35737 (file_number) — Commission File Number
- 94-3306718 (tax_id) — IRS Employer Identification No.
- 4800 Montgomery Lane, Suite 800 Bethesda, Maryland 20814 (address) — Principal Executive Offices
- (240) 497-9024 (phone_number) — Registrant's telephone number
FAQ
What type of material definitive agreement did Northwest Biotherapeutics enter into?
Northwest Biotherapeutics entered into a loan agreement.
On what date was the earliest event reported in this filing?
The earliest event reported was on December 19, 2024.
What is the principal executive office address of Northwest Biotherapeutics?
The principal executive office is located at 4800 Montgomery Lane, Suite 800, Bethesda, Maryland 20814.
What is the Commission File Number for Northwest Biotherapeutics?
The Commission File Number is 0-35737.
What is the IRS Employer Identification Number for the company?
The IRS Employer Identification Number is 94-3306718.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-12-26 16:29:14
Key Financial Figures
- $0.001 — registered: Common Stock, par value, $0.001 per share NWBO OTCQB Indicate by
Filing Documents
- tm2432020d2_8k.htm (8-K) — 24KB
- tm2432020d2_ex99-1.htm (EX-99.1) — 10KB
- tm2432020d2_ex99-1img001.jpg (GRAPHIC) — 10KB
- 0001104659-24-131723.txt ( ) — 219KB
- nwbo-20241219.xsd (EX-101.SCH) — 3KB
- nwbo-20241219_lab.xml (EX-101.LAB) — 33KB
- nwbo-20241219_pre.xml (EX-101.PRE) — 22KB
- tm2432020d2_8k_htm.xml (XML) — 4KB
01
Item 1.01. Entry Into A Material Definitive Agreement. On December 26, 2024, Northwest Biotherapeutics (OTCQB:NWBO) (the "Company") issued a press release, attached hereto as Exhibit 99.1, in which it provided information regarding its entry into a convertible note financing and standy equity purchase agreement.
03
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits No. Description 99.1 Press Release of Northwest Biotherapeutics, Inc. dated December 26, 2024. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NORTHWEST BIOTHERAPEUTICS, INC. Date: December 26, 2024 By: /s/ Linda Powers Name: Linda Powers Title: Chief Executive Officer and Chairman